Boston Scientific vs GE HealthCare Technologies
BSX and GEHC side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BSX and GEHC compare
Boston Scientific is the larger company, worth 1.8 times as much as GE HealthCare Technologies ($60.8B against $34.6B).
On earnings, Boston Scientific is cheaper: it trades at 17.0× trailing earnings, against 17.6× for GE HealthCare Technologies.
Boston Scientific grew revenue faster over the last twelve months (13.5% versus 6.5% for GE HealthCare Technologies).
GE HealthCare Technologies pays a dividend yielding 0.19%; Boston Scientific does not pay one.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BSX | GEHC |
|---|---|---|
| Size and price | ||
| Market cap | $60.8B | $34.6B |
| Share price | $41.98 | $76.57 |
| Change, 1 year | −58.1% | −1.0% |
| Change, 5 years | −2.7% | – |
| Beta (5Y) | 0.77 | 1.20 |
| Employees | 59K | 54K |
| StockData Score | ||
| Total score | 14 | 14 |
| Valuation score | 6 (better) | 4 |
| Growth score | 4 (better) | 1 |
| Performance score | 1 | 4 (better) |
| Health score | 3 (better) | 2 |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | 17.0× (better) | 17.6× |
| P/S | 2.9× | 1.6× (better) |
| P/B | 2.4× (better) | 3.2× |
| EV/EBITDA | 13.1× (better) | 15.6× |
| P/FCF | 16.8× (better) | 21.9× |
| PEG | 0.27 (better) | 6.91 |
| FCF yield | 6.0% (better) | 4.6% |
| Fair value | $93.08 | $83.67 |
| Margin of safety | 54.9% (better) | 8.5% |
| Growth | ||
| Revenue growth (TTM) | 13.5% (better) | 6.5% |
| Revenue growth, 5Y average | 15.2% | – |
| Net income growth (TTM) | – | −11.4% |
| EPS growth (TTM) | 47.0% (better) | −10.7% |
| Profitability | ||
| Gross margin | 69.9% (better) | 39.5% |
| Operating margin | 19.8% (better) | 12.9% |
| Net margin | – | 9.3% |
| FCF margin | 17.3% (better) | 7.4% |
| Return on equity | – | 19.2% |
| Return on invested capital | 11.2% | 11.3% (better) |
| Financial health | ||
| Debt / equity | 0.51 (better) | 0.92 |
| Net debt / EBITDA | 2.17 (better) | 2.93 |
| Interest coverage | 11.4× | – |
| Current ratio | 1.24 | 1.26 (better) |
| Altman Z-score | 2.87 (better) | 1.91 |
| Piotroski F-score | – | 5 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.19% |
| Payout ratio | – | 3.2% |
| Years of dividend growth | – | 2 |
| Buyback yield | – | 1.2% |
| Shareholder yield | 0.00% | 1.3% (better) |
| Ownership | ||
| Held by institutions | 92.1% | 87.3% |
| Held by insiders | 0.19% | 0.33% |
| Insider net buying, 12 months | −$13.0M | $6.4M (better) |
| Superinvestors holding | 1 | 5 (better) |
| Short interest, % of float | 2.9% | 4.1% |
Go deeper
- BSX stock overview
- BSX income statement
- BSX valuation and score
- GEHC stock overview
- GEHC income statement
- GEHC valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.